Favorite this paper

Malaria has provided a major selective pressure and has modulated the genetic diversity in the recent history of the human genome. Increasing evidence has pointed to erythrocyte surface antigen variants that have resulted from evolutionary selection by malaria, as the variants of FY gene (coding for the Duffy Antigen/Receptor for Chemokines - DARC), particularly the FY*02N.01 allele. DARC is the main receptor used for P. vivax toinvade reticulocytes. The polymorphism −67T>C in the gene promoter (defines FY*02N.01 allele) ablates its expression on erythrocytes. This variant is highly frequent in sub-Saharan African populations and accounts for the remarkable absence of P. vivax infection among humans in this region. DARC has two immunologically distinct antigens (products of the alleles FY*A and FY*B) that was recently suggested to influence susceptibility to infection by P. vivax. Here, we sought to investigate if DARC variation has modulated susceptibility to P. vivax malaria in individuals (N=339) from an agricultural settlement of Amazon Region (Rio Pardo/AM). Initially, genetic ancestry was estimated for these individuals pointing to a highly admixture population with significant contribution of European (43.8%) and Native American (37.8%) ancestry, with a low African ancestry (18.4%). The estimated individual ancestry was associated with DARC genotype by fitting a multinomial logistic model. A consistent finding is that the odds of having the FY*B/FY*B and FY*A/FY*Agenotypes rises continuously with the increase of European and Native American ancestry, respectively. To determine if polymorphisms in DARC affect susceptibility to clinical P. vivax malaria the number of malaria episodes was recorded for each participant during a period of 11 years. Zero-inflated Poisson Regression (ZIP) analysis adjusting for place of residence and time of residence in the endemic area showed a reduction in the risk of P. vivax malaria of 90% and 15% for subjects with FY*02N.01/FY*02N.01 and FY*A/FY*02N.01 genotypes, respectively, compared to the reference genotype FY*A/FY*B. In contrast, subjects with FY*B/FY*02N.01 genotype showed a greater risk (38%) of clinical malaria. In our knowledge this is the first population based-study to investigate how genetic ancestry has reflected on the distribution of DARC genotypes and, thus, influenced in susceptibility to malaria.